Ramucirumab Drug Aliquot | Anti-VEGFR2 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Ramucirumab are now available as research consumables.

Ramucirumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Ramucirumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Ramucirumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Cyramza® / Ramucirumab Reference Product

Drug nameCyramza®
API typeRamucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced
angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF
Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits
ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components,
including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and
migration of human endothelial cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/14/957/001 - 003
Marketing authorisation holder
Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands
Name of the manufacturer of the biological active substance
ImClone Systems LLC
33 ImClone Drive,
New Jersey
NJ 08876
Eli Lilly S.A.
County Cork
Name and address of the manufacturer(s) responsible for batch releaseLilly, S.A.
Avda de la Industria, 30
28108 Madrid
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
Histidine monohydrochloride
Sodium chloride
Glycine (E640)
Polysorbate 80 (E433)
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.